嗜伊紅性食道炎市場：商業機會、成長要素、產業趨勢分析及2026-2035年預測

全球嗜伊紅性食道炎市場預計到 2025 年價值 4.777 億美元，預計到 2035 年將達到 75 億美元，複合年成長率為 31.8%。

嗜伊紅性食道炎市場正受到該疾病盛行率上升和醫療專業人員認知度提高的推動。該疾病是由於特定免疫細胞在食道內積聚而引起的發炎和組織損傷，需要長期管理。嗜伊紅性食道炎市場也受益於患者認知度的提高和診斷技術的進步，從而能夠早期發現和早期療育。此外，標靶治療的日益普及正在改變治療方法並改善患者預後。隨著醫療保健系統越來越重視慢性病管理和個人化醫療，預計嗜伊紅性食道炎市場將在多個地區實現顯著成長。

嗜伊紅性食道炎市場正受益於患者和醫療專業人員對該疾病認知度的不斷提高，從而推動了對先進治療方案的需求。此疾病在各年齡層的診斷率均上升，進一步增加了治療需求。此外，生物製藥和標靶治療等創新治療方法的引入也促進了嗜伊紅性食道炎市場的發展，這些療法能夠針對該疾病的潛在機制。這些進展正在改善臨床療效並擴大治療選擇，從而支持市場的持續成長。

預計到2025年，皮質類固醇市場規模將達到1.79億美元，由於其強大的抗發炎作用，仍是主要的治療類別之一。這些治療方法廣泛用於症狀控制，通常被視為第一線治療方法。嗜伊紅性食道炎市場受益於皮質類固醇在抑制發炎和改善患者舒適度方面的有效性，這也支持了其在臨床實踐中的持續應用。

預計到2035年，口服藥物市場規模將達32億美元。市場之所以不斷擴張，是因為服用方便，與其他給藥方式相比，口服藥物更容易使用。嗜伊紅性食道炎市場也受益於針對特定生物路徑、提高治療精準度和療效的口服療法的持續研發。此外，口服藥物安全性較高、全身性副作用較少，也是促使消費者越來越傾向選擇口服藥物的原因之一。

預計到2025年，北美嗜伊紅性食道炎市場佔有率將達到45.5%，這主要得益於嗜伊紅性食道炎基礎設施和創新治療方法的積極應用。該地區市場受益於較高的疾病認知度、強大的診斷能力以及便利的專科醫療服務。新療法的不斷湧現和完善的分銷網路將進一步推動市場長期成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 嗜伊紅性食道炎盛行率增加
    • 診斷技術的進步
    • 標靶藥物療法的研發
    • 加大對醫療保健領域的投資
  • 產業潛在風險與挑戰
    • 學名藥的競爭
    • 醫療成本不斷上漲
  • 市場機遇
    • 非侵入性診斷和監測工具的擴展
    • 基於個人化和精準醫療的嗜酸性粒細胞性治療方法已廣泛應用。
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
  • 歐洲
  • 亞太地區
• 專利分析
• 管道分析
• 人工智慧和生成式人工智慧的影響
• 未來市場趨勢（基於初步研究）
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依藥物類別分類，2022-2035年

• 生物製藥
• 皮質類固醇
• 質子幫浦阻斷劑
• 免疫調節藥物
• 其他藥物分類

第6章 市場估計與預測：依給藥途徑分類，2022-2035年

• 口服
• 注射藥物
• 外用

第7章 市場估計與預測：依年齡層別分類，2022-2035年

• 兒童
• 成人版
• 老年人

第8章 市場估算與預測：依通路分類，2022-2035年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Allakos
• Arena Pharmaceuticals
• AstraZeneca
• Cipla
• Ellodi Pharmaceuticals
• EsoCap
• GlaxoSmithKline
• Revolo Biotherapeutics
• Sanofi
• Sun Pharmaceutical
• Takeda Pharmaceutical Company
• Teva Pharmaceutical

The Global Eosinophilic Esophagitis Market was valued at USD 477.7 million in 2025 and is estimated to grow at a CAGR of 31.8% to reach USD 7.5 billion by 2035.

The eosinophilic esophagitis market is driven by the rising prevalence of the disease and improved recognition among healthcare professionals. This condition involves the accumulation of specific immune cells in the esophagus, leading to inflammation and tissue damage that require long-term management. The eosinophilic esophagitis market is also benefiting from increasing patient awareness and advancements in diagnostic capabilities, which are enabling earlier detection and intervention. In addition, the growing availability of targeted therapies is transforming treatment approaches and improving patient outcomes. As healthcare systems place greater emphasis on chronic disease management and personalized medicine, the eosinophilic esophagitis market is expected to witness substantial growth across multiple regions.

The eosinophilic esophagitis market is further supported by rising awareness among both patients and healthcare providers, which is increasing demand for advanced therapeutic solutions. The condition is being more frequently identified across different age groups, contributing to expanding treatment needs. The eosinophilic esophagitis market is also benefiting from the introduction of innovative therapies, including biologics and targeted treatment approaches that address underlying disease mechanisms. These advancements are improving clinical outcomes and expanding available treatment options, supporting continued market development.

The corticosteroids segment reached USD 179 million in 2025 and remains a key treatment category due to its strong anti-inflammatory effects. These therapies are widely utilized for symptom management and are often considered a primary treatment approach. The eosinophilic esophagitis market benefits from the effectiveness of corticosteroids in controlling inflammation and improving patient comfort, supporting their continued adoption in clinical practice.

The oral segment is projected to reach USD 3.2 billion by 2035. This segment is expanding due to the convenience and accessibility of oral treatment options, which allow for easier administration compared to alternative methods. The eosinophilic esophagitis market is also supported by the ongoing development of oral therapies that target specific biological pathways, improving treatment precision and effectiveness. Enhanced safety profiles and reduced systemic side effects are further contributing to the growing preference for oral medications.

North America Eosinophilic Esophagitis Market accounted for 45.5% share in 2025, driven by advanced healthcare infrastructure and strong adoption of innovative treatments. The eosinophilic esophagitis market in this region is supported by high awareness levels, robust diagnostic capabilities, and access to specialized care. Continued introduction of new therapies and strong distribution networks are further sustaining long-term growth.

Key companies operating in the Global Eosinophilic Esophagitis Market include AstraZeneca, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, Cipla, Teva Pharmaceutical, Allakos, Arena Pharmaceuticals, Revolo Biotherapeutics, Ellodi Pharmaceuticals, EsoCap, and Sun Pharmaceutical. Companies in the Global Eosinophilic Esophagitis Market are strengthening their market presence through innovation and strategic collaborations. Many players are investing heavily in research and development to introduce targeted therapies and biologics that address unmet clinical needs. Partnerships with research institutions and healthcare providers are enabling faster development and commercialization of new treatments. Companies are also focusing on expanding their product pipelines and gaining regulatory approvals to enhance market reach. In addition, increasing investment in patient awareness programs and physician education is supporting early diagnosis and treatment adoption.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Age group trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of eosinophilic esophagitis
    • 3.2.1.2 Advancement in diagnostic techniques
    • 3.2.1.3 Development of target drug therapies
    • 3.2.1.4 Increasing healthcare investment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from generic drugs
    • 3.2.2.2 High cost of treatment
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of non-invasive diagnostic and monitoring tools
    • 3.2.3.2 Rising adoption of personalized and precision-based EoE therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Patent analysis
• 3.6 Pipeline analysis
• 3.7 Impact of AI & GEN AI
• 3.8 Future market trends (Driven by Primary Research)
• 3.9 Impact of AI and generative AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Biologics
• 5.3 Corticosteroids
• 5.4 Proton pump inhibitors
• 5.5 Immunomodulators
• 5.6 Other drug class

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Age Group, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Allakos
• 10.2 Arena Pharmaceuticals
• 10.3 AstraZeneca
• 10.4 Cipla
• 10.5 Ellodi Pharmaceuticals
• 10.6 EsoCap
• 10.7 GlaxoSmithKline
• 10.8 Revolo Biotherapeutics
• 10.9 Sanofi
• 10.10 Sun Pharmaceutical
• 10.11 Takeda Pharmaceutical Company
• 10.12 Teva Pharmaceutical